MPTP诱导的食蟹猴偏侧帕金森病模型运动行为学的长期动态评价研究

doi:10.3969/j.issn.1006-7795.2018.02.013

摘要/Abstract

摘要： 目的建立具有长期运动行为学改变的灵长类动物模型，用于研究神经保护性药物的研究。利用不同运动变化评估方法探讨1-甲基-4-苯基-1，2，3，6-四氢吡啶（1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine，MPTP）诱导的食蟹猴偏侧帕金森病（Parkinson's disease，PD）模型运动行为学的长期动态变化。方法 5只（6~7岁）健康雄性食蟹猴分别于左侧颈内动脉注射MPTP建立偏侧PD模型。在MPTP注射前（基线），注射后3、6个月及1、3、6年分别进行临床评分；在MPTP注射前，注射后3、6个月及1年和6年分别进行24 h躯体自发运动总量行为监测。结果造模后3个月临床评分（14.65±8.41）增高到达高峰，造模6个月后临床评分（8.10±2.01）仍较基线高，但与3个月时比较显著降低（P=0.006）；之后维持稳定，直至造模6年后临床评分与6个月时比较差异无统计学意义。而24 h躯体自发运动总量造模后3个月降低最明显（16 597.79±12 488.87），造模后6个月有所恢复（29 278.02±12 264.66），但与基线（50 084.20±30 170.89）比较仍显著性降低（与3、6个月比，P值分别为0.014，0.016）；造模1年和6年后的24 h躯体自发运动总量恢复到基线水平。结论颈内动脉注射MPTP可以诱导形成稳定具有长期运动症状的偏侧PD模型，尤其是临床评分的改变，直到造模后6年仍存在异常。

关键词: 帕金森病, 食蟹猴, 运动行为学, 1-甲基-4-苯基-1, 2, 3, 6-四氢吡啶

Abstract: Objective To establish long lasting changes of motor function in MPTP-induced non-human primate models for investigating neuroprotective therapy. We try to study the dynamic changes of motor function of MPTP-induced unilateral Parkinson's disease model in cynomolgus monkeys. Methods Total 5 healthy male cynomolgus monkeys (6~7 years old) were injected MPTP into the left internal carotid artery. The motor behavior changes were evaluated by clinical rating score and physical activity monitoring before and after MPTP injection at 3 and 6 months, 1, 3, and 6 years. Results The clinical rating score was significantly increased and reached the peak (14.65±8.41) at 3 months and partially recovered at 6 months (8.10±2.01, P=0.006), but maintained stable to 6 years after MPTP injection. The 24 h physical activity was significantly decreased and reached the peak at 3 months (16 597.79±12 488.87, P=0.014), 6 months (29 278.02±12 264.66, P=0.016) but recovered to the baseline level (50 084.20±30 170.89) after 1 year. Conclusion The results suggest that the motor deficit assessed by clinical rating score of MPTP-induced unilateral Parkinson's disease model in cynomolgus monkeys can last up to 6 years.

Key words: Parkinson's disease, cynomolgus monkeys, motor behavior, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)

中图分类号:

R742.5

罗斌斌, 胡亚松, 岳峰, 陈彪. MPTP诱导的食蟹猴偏侧帕金森病模型运动行为学的长期动态评价研究[J]. 首都医科大学学报, 2018, 39(2): 217-222.

Luo Binbin, Hu Yasong, Yue Feng, Chen Biao. Long lasting changes of motor function in MPTP-induced unilateral cynomolgus monkeys model[J]. Journal of Capital Medical University, 2018, 39(2): 217-222.

参考文献

[1] Ponsford J P. Therapies for dopaminergic-induced dyskinesias in parkinson disease[J]. Ann Neurol, 2011, 70(4):667.
[2] Zhang J, Stanton D M, Nguyen X V, et al. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits[J]. Neuroscience, 2005, 135(3):829-838.
[3] Riedel O, Klotsche J, Spottke A, et al. Frequency of dementia, depression, and other neuropsychiatric symptoms in 1,449 outpatients with Parkinson's disease[J]. J Neurol, 2010, 257(7):1073-1082.
[4] de Lau L M, Breteler M M. Epidemiology of Parkinson's disease[J]. Lancet Neurol, 2006, 5(6):525-535.
[5] Choi D Y, Zhang J, Bing G. Aging enhances the neuroinflammatory response and alpha-synuclein nitration in rats[J]. Neurobiol Aging, 2010, 31(9):1649-1653.
[6] 户乃丽, 刘玉军, 徐群渊,等. 黑质内炎症反应对恒河猴多巴胺能神经元的毒性作用[J]. 解剖学报, 2009, 40(5):732-736.
[7] Zenzola A, Masi G, De Mari M, et al. Fatigue in Parkinson's disease[J]. Neurol Sci, 2003, 24(3):225-226.
[8] Zhang J R, Chen J, Yang Z J, et al. Rapid eye movement sleep behavior disorder symptoms correlate with domains of cognitive impairment in parkinson's disease[J]. Chin Med J(Engl), 2016, 129(4):379-385.
[9] Pessoa Rocha N, Reis H J, Vanden Berghe P, et al. Depression and cognitive impairment in parkinson's disease:a role for inflammation and immunomodulation?[J]. Neuroimmunomodulation, 2014, 21(2-3):88-94.
[10] Sateia M J. International classification of sleep disorders-third edition:highlights and modifications[J]. Chest, 2014, 146(5):1387-1394.
[11] Jingzhong Z, Hui Y, Deyi D, et al. Long-term therapeutic effects on parkinsonian rats of intrastriatal co-grafts with genetically engineered fibroblasts expressing tyrosine hydroxylase and glial cell line-derived neurotrophic factor[J]. Int J Neurosci, 2005, 115(6):769-779.
[12] Sulzer D, Surmeier D J. Neuronal vulnerability, pathogenesis, and parkinson's disease[J]. Mov Disord, 2013, 28(1):715-724.
[13] Lorigados L,Alvarez P, Pavón N, et al. NGF in experimental models of Parkinson disease[J]. Mol Chem Neuropathol, 1996, 28(1-3):225-228.
[14] Kurlan R, Kim M H, Gash D M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys:assessment with a new rating scale for monkey parkinsonism[J]. Mov Disord, 1991, 6(2):111-118.
[15] Domino E F, Ni L. Trihexyphenidyl potentiation of l-DOPA:reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys[J]. Exp Neurol, 1998, 152(2):238-242.
[16] Emborg-Knott M E, Domino E F. MPTP-induced hemiparkinsonism in nonhuman primates 6-8 years after a single unilateral intracarotid dose[J]. Exp Neurol, 1998, 152(2):214-220.
[17] Yagi S, Yoshikawa E, Futatsubashi M, et al. Progression from unilateral to bilateral parkinsonism in early Parkinson disease:implication of mesocortical dopamine dysfunction by PET[J]. J Nucl Med, 2010, 51(8):1250-1257.
[18] Wood H. Parkinson disease:18F-DTBZ PET tracks dopaminergic degeneration in patients with Parkinson disease[J]. Nat Rev Neurol, 2014, 10(6):305.
[19] Ghaemi M, Raethjen J, Hilker R, et al. Monosymptomatic resting tremor and Parkinson's disease:a multitracer positron emission tomographic study[J]. Mov Disord, 2002, 17(4):782-788.
[20] Chen M, Wang T, Yue F, et al. Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral alpha-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys[J]. Neuroscience, 2015, 286:383-392.
[21] Hawkes C H, Del Tredici K, Braak H. Parkinson's disease:a dual-hit hypothesis[J]. Neuropathol Appl Neurobiol, 2007, 33(6):599-614.
[22] Yue F, Zeng S, Tang R, et al. MPTP induces systemic parkinsonism in middle-aged cynomolgus monkeys:clinical evolution and outcomes[J]. Neurosci Bull, 2017, 33(1):17-27.
[23] Sonni I, Fazio P, Schain M, et al. Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in ealthy controls and parkinson disease patients[J]. J Nucl Med, 2016, 57(10):1529-1534.
[24] Emborg M E, Shin P, Roitberg B, et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys[J]. Exp Neurol, 2001, 168(1):171-182.
[25] Blini E, Romeo Z, Spironelli C, et al. Multi-tasking uncovers right spatial neglect and extinction in chronic left-hemisphere stroke patients[J]. Neuropsychologia, 2016, 92:147-157.
[26] Bhidayasiri R, Trenkwalder C. Getting a good night sleep? The importance of recognizing and treating nocturnal hypokinesia in Parkinson's disease[J]. Parkinsonism Relat Disord, 2018[Epub ahead of print].
[27] Louter M, Maetzler W, Prinzen J, et al. Accelerometer-based quantitative analysis of axial nocturnal movements differentiates patients with Parkinson's disease, but not high-risk individuals, from controls[J]. J Neurol Neurosurgery Psychiatry, 2015, 86(1):32-37.
[28] Nero H, Benka Wallén M, Franzen E, et al. Objectively assessed physical activity and its association with balance, physical function and dyskinesia in parkinson's disease[J]. J Parkinsons Dis, 2016, 6(4):833-840.
[29] Jan C, Pessiglione M, Tremblay L, et al. Quantitative analysis of dopaminergic loss in relation to functional territories in MPTP-treated monkeys[J]. Eur J Neurosci, 2003, 18(7):2082-2086.
[30] Zhang Z, Weeks R, Grondin R, et al. Similarities and differences in cognitive deficits and responsiveness to L-Dopa between aged and MPTP-treated cynomolgus monkeys tested on the same tasks[J]. J Gerontol Geriatr Res, 2014, 3:5.